Invivyd, Inc. (NASDAQ:IVVD) Q2 2023 Earnings Call Transcript

And so we feel that it provides us a higher probability of duration of activity. And so that’s what we continue to look at and test, but we think that’s probably the most critical advantage, which is being able to have prolonged activity as our hypothesis for 222. Beyond that, we continue to see that by utilizing the adintrevimab, the ADG20 data, that allows this platform as well to be quite a significant advantage. As we said, we see that Invivyd is one of a few companies who could utilize existing data that was done previously. And that’s quite an advantage as it relates to pursuing EUAs in a much faster fashion than running full clinical endpoint studies, especially given the current environment and looking to recruit patients.

Patrick Trucchio: Okay. Thank you so much.

Operator: And I am not showing any further questions at this time. I would like to turn the call back over to Dave for any closing remarks.

Dave Hering: Thank you all for joining the call today. It’s a very exciting time for Invivyd as we get closer to milestones that we believe would be quite impactful for patients, our organization and shareholders. We thank you for your continued support and interest in Invivyd, and we will look forward to catching up with any of you individually over the coming days. Thank you so much.

Operator: Ladies and gentlemen, this does conclude today’s presentation. You may now disconnect and have a wonderful day.